[Clinical immunological rationale of interferon therapy in chronic bacterial prostatitis].

The study of changes in the immune status of patients with chronic bacterial prostatitis demonstrated changes in immunological parameters reflecting depression of the immune system (subnormal levels of interferon alpha, gamma, sIgA, functional activity of neutrophils, high concentration of IgA, IgG, IgM). Thus, combined treatment of chronic bacterial prostatitis must include administration of immunomodulators.

[Vitaprost plus in the treatment of chronic bacterial prostatitis].

Our study has demonstrated that compound medicine vitaprost plus in therapy of chronic bacterial prostatitis (CBP) reduces intensity of prostatic inflammation, significantly relieves symptoms of chronic prostatitis and pain syndrome. The absence of unwanted side effects, significant changes in clinical and biochemical blood and urine parameters evidences for good tolerance and safety of the drug. Thus, rectal suppositories vitaprost plus can be recommended for treatment of chronic bacterial prostatitis caused by both gram-positive and gram-negative bacteria in patients of different age and clinical symptoms.

[Administration of oral vitaprost for prevention of exacerbations of chronic abacterial prostatitis].

Active substance of vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostate. The prostatic extract has an organotropic action in relation to the prostate. As all peptide bioregulators, prostatic extract has antiaggregant and anticoagulant properties, enhances synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostatic gland.

[Vitaprost forte in the therapy of patients with prostatic adenoma].

Active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland. Prostatic extract has an organotropic effect in respect to the prostatic gland. It inhibits proliferative activity of cells and, therefore, development of prostatic adenoma, reduces edema and inflammation activity in prostatic diseases.